No Data
Research Reports Mining丨Guosheng Securities: Eyebright Medical Technology (Beijing) Co., Ltd. Longjing PR approved, maintaining a Buy rating.
Guosheng Securities' Research Reports point out that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) has received approval for the III class registration certificate for its intraocular lens and is now on the market. Longjing PR is the first domestically developed posterior chamber intraocular lens, innovatively using Balacrylic balanced acrylic material, featuring a unique aspherical double concave design with a wide-open peripheral arch, reducing the risk of peripheral contact with the artificial lens. The results of the 5-year clinical trials have been released, and multidimensional indicators show that Longjing PR outperforms ICL. Maintain a Buy rating.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): The crystal eye artificial lens has been approved for listing through the special review procedure for Innovative Medical Management.
On January 7, Gelonghui reported that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that its "artificial crystalline lens for phakic eyes" has recently been approved for registration by the National Medical Products Administration through a special review for Innovative Medical Management medical instruments. The artificial crystalline lens for phakic eyes is a refractive artificial lens, and this product is based on innovative balanced acrylic material, featuring a zero spherical aberration design with a large optical zone and a double concave stabilizing arch height design. Once implanted in the eye, it can serve as a refractive component, effectively reducing/correcting myopia and providing patients with high-quality postoperative visual acuity.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): The plan for the Chairman and some Directors and senior management to increase their shareholding in the company has been completed.
Gelonghui reported on December 23 that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that from June 20, 2024, to December 20, 2024, the company's controlling shareholder, actual controller, Chairman and General Manager Mr. Xie Jiangbing, Director and senior management Ms. Wang Zhao, and senior management Mr. Jia Baoshan cumulatively increased their shareholding in the company by 45,109 shares through the centralized bidding trading method via the Shanghai Exchange, accounting for 0.0238% of the company's current total equity, with a total increase amount of 3.4366 million yuan (excluding stamp duty, transaction commission, and other trading costs), which has surpassed this increase.
Shareholder Bai Ying of eyebright medical technology (beijing) co., ltd. (688050.SH) intends to reduce shareholding by no more than 1.5%.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that shareholder Bai Ying, who holds 5.63% of the shares, plans to conduct a block trade...
688050 Aibo Healthcare 2024 Third Quarter Report
eyebright medical technology (beijing) co., ltd. (688050.SH): The net income for the first three quarters was 0.318 billion yuan, a year-on-year increase of 26.04%.
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. (688050.SH) announced on October 29th that in the first three quarters of 2024, it achieved a total operating income of 1.075 billion yuan, a year-on-year increase of 60.94%; net income attributable to shareholders of the parent company was 0.318 billion yuan, a year-on-year increase of 26.04%; and the basic earnings per share was 1.68 yuan.
